Theragenics completes $68M sale to private equity outfit Juniper

A private equity firm has completed its $68.3 million purchase of Theragenics, a struggling Georgia maker of surgical tools and prostate cancer treatments. Juniper's acquisition of the company follows approval of the deal by Theragenics shareholders at an Oct. 17, 2013, special meeting. The sale price: about $2.20 per share in cash. Theragenics CEO M. Christine Jacobs is slated to retire, and current CFO Frank Tarallo will step in and replace her. Theragenics has faced sales declines in its surgical products and brachytherapy seeds businesses, and the company is shifting some manufacturing to Latin America. Item

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.